Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study

Objectives Prolonged intubation can lead to tracheal stenosis, resulting in significant morbidity and impaired quality of life, and in severe cases, results in requiring tracheostomies or invasive surgery to survive. This subgroup analysis evaluated the safety and efficacy of a semicompliant paclitaxel drug‐coated balloon (DCB) in tracheostomy patients with tracheal stenosis. Methods This is a subgroup analysis from a prospective, multicenter, single‐arm, open‐label study. Patients received debulking, either laser or coblation, prior to DCB dilation. Results Seventeen participants with tracheostomies and tracheal stenoses at baseline were treated at three sites. Etiology was postintubation trauma for 94.1% (16/17) and infectious for one participant. There were four total occlusions (Myer‐Cotton Grade 4) and 11 Grade 3 stenoses. The average stenosis length was 1.68 cm. Freedom from major adverse events at 1 month was 100% (17/17), with 1 procedure‐related serious adverse event (SAE). Successful decannulation rate was 100% within 12 months posttreatment. Kaplan–Meier freedom from target lesion reintervention (TLR) was 70.6% at 6 months and 64.7% at 12 months. SF‐12 physical component scores were significantly improved ( p < 0.05). No patients required open surgery by 12 months. Conclusion Paclitaxel DCB appears to be safe to use in the airway. At 12 months, tracheostomy participants experienced low rates of TLR, improved quality of life, no device‐related SAEs, and a high tracheostomy closure rate without the need for invasive surgery. The local antiproliferative effects of the paclitaxel DCB show promise in preventing reinterventions and may provide an option for inoperable patients or postsurgical restenosis treatment. Level of Evidence 4

Authors

Institutions

Publication Details

Journal
Laryngoscope Investigative Otolaryngology
Published
2026-11-20
DOI
https://doi.org/10.1002/lio2.70642
Primary Topic
Tracheal and airway disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study

Angélica Santos, Teona Mskhaladze, Fabio Vega, Ellen M. O’Malley et al.
Laryngoscope Investigative Otolaryngology
Tracheal and airway disorders
article

Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study

Angélica Santos, Teona Mskhaladze, Fabio Vega, Ellen M. O’Malley, Sabrina Zapata
article en

Abstract

Objectives Prolonged intubation can lead to tracheal stenosis, resulting in significant morbidity and impaired quality of life, and in severe cases, results in requiring tracheostomies or invasive surgery to survive. This subgroup analysis evaluated the safety and efficacy of a semicompliant paclitaxel drug‐coated balloon (DCB) in tracheostomy patients with tracheal stenosis. Methods This is a subgroup analysis from a prospective, multicenter, single‐arm, open‐label study. Patients received debulking, either laser or coblation, prior to DCB dilation. Results Seventeen participants with tracheostomies and tracheal stenoses at baseline were treated at three sites. Etiology was postintubation trauma for 94.1% (16/17) and infectious for one participant. There were four total occlusions (Myer‐Cotton Grade 4) and 11 Grade 3 stenoses. The average stenosis length was 1.68 cm. Freedom from major adverse events at 1 month was 100% (17/17), with 1 procedure‐related serious adverse event (SAE). Successful decannulation rate was 100% within 12 months posttreatment. Kaplan–Meier freedom from target lesion reintervention (TLR) was 70.6% at 6 months and 64.7% at 12 months. SF‐12 physical component scores were significantly improved ( p < 0.05). No patients required open surgery by 12 months. Conclusion Paclitaxel DCB appears to be safe to use in the airway. At 12 months, tracheostomy participants experienced low rates of TLR, improved quality of life, no device‐related SAEs, and a high tracheostomy closure rate without the need for invasive surgery. The local antiproliferative effects of the paclitaxel DCB show promise in preventing reinterventions and may provide an option for inoperable patients or postsurgical restenosis treatment. Level of Evidence 4

Laryngoscope Investigative OtolaryngologyVol. 11(6)
Hospital Punta Pacifica (PA), Guyra Paraguay (PY), Hospital de Clínicas (UY)
Tracheal and airway disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon